Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10997512 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AALDH1A1EPHX2NR1H4 | |
| SCHEMBL12641164 | 0.83 | CA2 (0.56) | SMN1; SMN2ALDH1A1EPHX2NR1H4KDM4E | |
| SCHEMBL748902 | 0.82 | GABRA5 (0.47) | SMN1; SMN2KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL12093593 | 0.80 | POLB (0.61) | SMN1; SMN2KMT2AALDH1A1EGFRL3MBTL1 | |
| SCHEMBL751293 | 0.80 | ESRRG (0.55) | SMN1; SMN2ALDH1A1EGFR | |
| SCHEMBL5896700 | 0.80 | DGAT1 (0.53) | SMN1; SMN2KMT2AALDH1A1EPHX2NR1H4 | |
| SCHEMBL5664574 | 0.80 | DGAT1 (0.50) | SMN1; SMN2KMT2AALDH1A1EPHX2NR1H4 | |
| SCHEMBL3523655 | 0.80 | TDP1 (0.60) | KMT2AALDH1A1MEN1L3MBTL1 | |
| SCHEMBL14158944 | 0.80 | ALDH1A1 (0.57) | SMN1; SMN2KMT2AALDH1A1MEN1EGFR | |
| SCHEMBL2002710 | 0.80 | EPHX2 (0.60) | SMN1; SMN2ALDH1A1EPHX2NR1H4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138209-B2 | Substituted picolinamides as MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SMN1; SMN2 3865/4885KMT2A 642/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.